Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 147
Filter
1.
Rev. Nutr. (Online) ; 36: e220103, 2023. tab, graf
Article in English | LILACS | ID: biblio-1521589

ABSTRACT

ABSTRACT Objective: This study aimed to evaluate the effect of baru nuts supplementation on body composition and metabolic profile in adults with type 2 diabetes. Methods: This is a randomized, placebo-controlled, crossover trial with 30 adults with type 2 diabetes. The assay had two periods of 12 weeks each, with a washout period of 12 weeks between treatments. The subjects were randomized and received the two treatments in alternate periods: supplementation of 30g baru nuts or placebo. Anthropometry, body composition, blood pressure, blood sampling, food intake, and physical activity data were analyzed. Results: Baru nut intake reduced waist circumference (p=0.032), compared to placebo group. In the intra-group analysis, baru nut intake reduced total cholesterol (p=0.012) and LDL-c (p=0.017). Conclusion: The daily intake of baru nuts improved abdominal adiposity. Therefore, these nuts should be included in the diet to improve the health status of adults with type 2 diabetes.


RESUMO: Objetivo: Avaliar o efeito da suplementação com amêndoa de baru sobre a composição corporal e perfil metabólico de adultos com diabetes Mellitus tipo 2. Métodos: Este é um estudo randomizado, placebo-controlado, crossover com 30 adultos com diabetes Mellitus tipo 2. O ensaio clínico foi dividido em dois períodos de 12 semanas cada, com um washout de 12 semanas entre os tratamentos. Os sujeitos foram randomizados e receberam dois tratamentos em períodos alternativos: suplementação com 30 g de amêndoa de baru ou placebo. Foram coletados dados referentes à antropometria, composição corporal, pressão arterial, amostras de sangue, ingestão de alimentos e práticas de atividade física. Resultados: A ingestão de amêndoa de baru reduziu a circunferência da cintura (p=0,032), em comparação com o grupo placebo. Na análise intragrupo, a ingestão de amêndoa de baru também reduziu o colesterol total (p=0,012) e LDL-c (p=0,017). Conclusão: A ingestão diária de amêndoa de baru melhorou a adiposidade abdominal, portanto, deve ser incluída na dieta para a melhora do estado de saúde de adultos com diabetes Mellitus tipo 2.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Body Composition , Dipteryx , Diabetes Mellitus, Type 2/metabolism , Placebos/therapeutic use , Cholesterol , Cross-Over Studies , Abdominal Circumference , Arterial Pressure
2.
Revista Digital de Postgrado ; 10(1): 262, abr. 2021. tab
Article in Spanish | LIVECS, LILACS | ID: biblio-1147578

ABSTRACT

El bloqueo del nervio peri prostático con lidocaína, proporciona un buen alivio del dolor en la realización de la biopsia prostática guiada por ultrasonido, pero el dolor post-procedimiento, puede llegar a ser significativo, la adición del supositorio de diclofenac, podría proporcionar alivio adicional. Se asignaron al azar pacientes en 2 grupos el grupo 1 bloqueo con lidocaína del plexo peri prostático + supositorio de diclofenac sódico y el grupo 2 bloqueo con lidocaína del plexo peri prostático + supositorio de placebo, realizando biopsia doble sextante, el dolor a varios intervalos después del procedimiento se registró en una escala visual análoga (EVA) de 0 a 10. Los 2 grupos fueron similares en cuanto a edad, volumen de próstata, antígeno prostático específico, diagnóstico histopatológico. Los pacientes que recibieron diclofenac tuvieron puntajes de dolor significativamente más bajos que los que recibieron placebo (2 frente a 3,35) p 0,02. La administración rectal de diclofenac antes de la realización de la biopsia de próstata es un procedimiento simple que alivia significativamente el dolor experimentado sin aumento en la morbilidad(AU)


The peri-prostatic nerve block with lidocaine, provides good pain relief in performing ultrasoundguided prostate biopsy, but the postprocedure pain can be significant, the addition of diclofenac suppository, could provide additional relief. Patients were randomly assigned in 2 groups to group 1 blockade with lidocaine of the prostatic peri plexus + suppository of diclofenac sodium and group 2 blockade with lidocaine of the prostatic peri plexus + placebo suppository, performing double sextant biopsy, pain at several intervals after the procedure was recorded on a visual analog scale (EVA) from 0 to 10. Thee 2 groups were similar in terms of age, prostate volume, prostate-specific antigen, histopathological diagnosis. Patients who received diclofenac had pain scores significantly lower than those who received placebo (2 vs. 3.35) p 0.02. Rectal administration of diclofenac before performing a prostate biopsy is a simple procedure that relieves significantly pain experienced without increased morbidity(AU)


Subject(s)
Humans , Male , Middle Aged , Aged , Aged, 80 and over , Prostate/pathology , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Diclofenac/therapeutic use , Anesthetics, Local/therapeutic use , Lidocaine/therapeutic use , Nerve Block/methods , Placebos/therapeutic use , Prostate/diagnostic imaging , Administration, Rectal , Prospective Studies , Pain Management/methods , Image-Guided Biopsy , Anesthesia, Local
5.
REME rev. min. enferm ; 24: e1318, fev.2020. tab, graf
Article in English, Portuguese | BDENF, LILACS | ID: biblio-1125471

ABSTRACT

RESUMO Objetivo: avaliar a efetividade das essências florais de Bach na redução dos níveis de estresse docente. Método: ensaio clínico controlado, randomizado, duplo-cego, com delineamento prospectivo. Foram utilizados na coleta de dados um formulário validado à luz da teoria de Betty Neuman e três instrumentos, um na perspectiva perceptiva (PSS-14), o outro na prevalência dos sinais e sintomas (LSS) e um de avaliação dos aspectos bioeletrográfico (FAAB). A amostra foi constituída de 27 professores da rede básica de ensino com estresse médio e alto, distribuídos em dois grupos: intervenção (GI) e que recebeu floral e placebo (GP). Resultados: o GI mostrou-se efetivo na redução do estresse, sendo estatisticamente significante intragrupo com a diminuição das médias dos escores do PSS-14 (p=0,004, LSS - p = 0,000) e da bioeletrografia (p=0,011); bem como entre grupos com p-valor de 0,035 para LSS e FAAB com p= 0,001. Conclusão: as essências florais do sistema Bach mostraram-se efetivos no cuidado do estresse docente com a reestruturação da linha flexível de defesa, refletindo melhor relacionamento do professor com os estressores intra, inter e extrapessoais. Este estudo está registrado no ReBEC com o nº. UTN: U1111-1208-4987.


RESUMEN Objetivo: evaluar la efectividad de las esencias florales de Bach para reducir los niveles de estrés del personal docente. Método: ensayo clínico controlado, aleatorizado, doble ciego con diseño prospectivo. En la recogida de datos se utilizó un formulario validado a la luz de la teoría de Betty Neuman y tres instrumentos: uno en la perspectiva perceptiva (PSS-14), otro en la prevalencia de signos y síntomas (LSS) y otro para la evaluación de aspectos bioelectrográficos (FAAB) La muestra consistió en 27 profesores de educación básica con estrés medio y alto, divididos en dos grupos: intervención (GI), que recibió esencias florales, y placebo (GP). Resultados: el GI demostró ser efectivo para la reducción del estrés, siendo estadísticamente significativo dentro del grupo con disminución en las puntuaciones medias del PSS-14 (p = 0.004, LSS - p = 0.000) y bioelectrografía (p = 0.011); así como entre grupos con un valor de p de 0.035 para LSS y FAAB con p = 0.001. Conclusión: las Flores de Bach demostraron ser efectivas en el manejo del estrés de los docentes con la reestructuración de la línea flexible de defensa, reflejando una mejor relación entre el profesor y los estresores intra, inter y extrapersonales. El presente estudio está registrado en ReBEC bajo el nº. UTN: U1111-1208-4987.


ABSTRACT Objective: to evaluate the effectiveness of Bach flower essences in reducing teachers' stress levels. Method: a controlled, randomized, and double-blind clinical trial with a prospective design. In data collection, a form validated in the light of Betty Neuman's theory and another three instruments were used, one in the perceptive perspective (PSS-14), the second in the prevalence of the signs and symptoms (LSS), and the third for the evaluation of the bio-electrographic aspects (FAAB). The sample consisted of 27 teachers from the basic education network, with medium and high levels of stress and divided into two groups: intervention group (IG), the one that received Bach flower essences, and placebo group (PG). Results: the IG proved to be effective in reducing stress, being statistically significant intra-group with the decrease in the mean scores of PSS-14 (p=0.004), LSS (p=0.000), and bioelectrography (p=0.011); as well as between groups with a p-value of 0.035 for LSS, and FAAB with p=0.001. Conclusion: the Bach flower essences proved to be effective in the care of teachers' stress with the re-structuring of the flexible line of defense, reflecting in a better relationship between the teacher and intra-, inter-, and extra-personal stressors. This study is registered in the ReBEC under UTN Nº U1111-1208-4987.


Subject(s)
Humans , Placebos/therapeutic use , Psychiatric Nursing , Stress, Psychological , Therapeutics , Flower Essences , Faculty/psychology , Educational Personnel/statistics & numerical data
7.
Odovtos (En línea) ; 21(3): 10-15, Sep.-Dec. 2019. graf
Article in English | LILACS, BBO | ID: biblio-1091488

ABSTRACT

ABSTRACT Understanding the possible effects that a patient's psycho-neurobiological processes (such as the nocebo effect) may have on the every-day dental treatments, could assist the clinicians in preventing the onset of adverse events not related directly with the clinical procedure. At the same time, employing pathways to trigger plausible placebo effects could aid the clinician to enhance the outcome of ordinary clinical procedures and the patient's perspective. Identified factors, which could lead both to positive or negative effects, may be present in different ways. Prior personal experiences, second-hand information, alternative medicine, catastrophizing or patient motivation; all could have an indirect effect in the treatment outcome. A well-informed clinician should use such factors to individualize each patient treatment.


RESUMEN Comprender los posibles efectos que los procesos psico-neurobiológicos de un paciente (como el efecto nocebo) pueden tener en los tratamientos dentales diarios, podría ayudar a los clínicos a prevenir la aparición de eventos adversos que no estén relacionados directamente con el procedimiento clínico. Al mismo tiempo, el uso de vías para favorecer posibles efectos placebo podría ayudar al clínico a mejorar el resultado de sus procedimientos rutinarios y la perspectiva del paciente. Los factores identificados, ya sean positivos o negativos, pueden estar presentes de diferentes maneras. Experiencias personales anteriores, información de segunda mano, medicina alternativa, actitud catastrófica o motivación del paciente; todos podrían tener un efecto indirecto en el resultado del tratamiento. Un médico bien informado debe usar dichos factores para individualizar el tratamiento de cada paciente.


Subject(s)
Placebos/therapeutic use , Dental Anxiety/psychology , Nocebo Effect , Comprehensive Dental Care
8.
Gac. méd. Méx ; 155(4): 363-368, jul.-ago. 2019. tab
Article in English, Spanish | LILACS | ID: biblio-1286519

ABSTRACT

Resumen Introducción: El uso de placebo se ha extendido en la práctica a pesar de ser polémico. En México, la práctica de medicina familiar es predominante institucional y trabaja con un cuadro básico de medicamentos. Objetivo: Determinar la frecuencia y actitud del médico familiar en la utilización de placebos en la práctica clínica. Método: Estudio transversal, observacional, multicéntrico, en 307 médicos familiares con práctica activa, en 27 estados de la República Mexicana. Se usó cuestionario con datos sociodemográficos, preguntas sobre frecuencia de uso y actitudes elaboradas por consenso. Se analizó con chi cuadrada. Resultados: 75 % utilizó placebos (IC 95 % = 69.7-79.4 %); 122 (39.7 %) placebos puros, principalmente agua (p < 0.05), y 220 (71.6 %) placebos impuros, principalmente vitaminas y exámenes de laboratorio. Los usaron más en pacientes con síntomas físicos no explicados médicamente (178, 45.5 %), incluidos 122 (31.2 %) pacientes “sanos preocupados” o con padecimientos crónicos (40, 12.5 %). Motivos de prescripción: 249 (81 %) por el efecto psicológico, cuando demostraron beneficio (176, 57 %), aun cuando implicara engaño (78, 25 %) o evidencia de eficacia insuficiente (57, 19 %). El principal motivo fue por insistencia del paciente. Conclusiones: Se utilizaron más placebos impuros, principalmente en pacientes sanos preocupados y en aquellos con padecimientos crónicos.


Abstract Introduction: The use of placebo has spread in clinical practice despite being controversial. In Mexico, the practice of family medicine is predominantly institutional and works with an essential medications list. Objective: To determine the frequency and family doctor attitude regarding the use of placebos in clinical practice. Method: Cross-sectional, observational, multicenter study of 307 family doctors with active practice in 27 states of the Mexican Republic. A questionnaire was used with sociodemographic data and consensus-developed questions about frequency of use and attitudes. For analysis, the square-chi test was used. Results: 75% used placebos (95% CI=69.7-79.4%); 122 (39.7%) used pure placebos, mainly water (p < 0.05), and 220 (71.6%), impure placebos, mainly vitamins and laboratory tests. They were used more in patients with medically unexplained physical symptoms (178, 45.5%), including 122 (31.2%) “healthy worried” patients, or who had chronic conditions (40, 12.5%). Reasons for prescription: 249 (81%) for the psychological effect, when they showed benefit (176, 57%), even when it implied deceiving (78, 25%) or insufficient evidence of efficacy (57, 19%). The main reason was because of patient insistence. Conclusions: More impure placebos were used, mainly in healthy worried patients and in those with chronic conditions.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Physicians, Family/statistics & numerical data , Placebos/therapeutic use , Practice Patterns, Physicians'/statistics & numerical data , Attitude of Health Personnel , Cross-Sectional Studies , Health Care Surveys , Family Practice/statistics & numerical data , Mexico
9.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 41(3): 245-253, May-June 2019. tab
Article in English | LILACS | ID: biblio-1011490

ABSTRACT

Objective: Bipolar depression is characterized by neurobiological features including perturbed oxidative biology, reduction in antioxidant levels, and a concomitant rise in oxidative stress markers. Bipolar depression manifests systemic inflammation, mitochondrial dysfunction, and changes in brain growth factors. The depressive phase of the disorder is the most common and responds the least to conventional treatments. Garcinia mangostana Linn, commonly known as mangosteen, is a tropical fruit. The pericarp's properties may reduce oxidative stress and inflammation and improve neurogenesis, making mangosteen pericarp a promising add-on therapy for bipolar depression. Methods: Participants will receive 24 weeks of either 1,000 mg mangosteen pericarp or placebo per day, in addition to their usual treatment. The primary outcome is change in severity of mood symptoms, measured using the Montgomery-Åsberg Depression Rating Scale (MADRS), over the treatment phase. Secondary outcomes include global psychopathology, quality of life, functioning, substance use, cognition, safety, biological data, and cost-effectiveness. A follow-up interview will be conducted 4 weeks post-treatment. Conclusion: The findings of this study may have implications for improving treatment outcomes for those with bipolar disorder and may contribute to our understanding of the pathophysiology of bipolar depression. Clinical trial registration: Australian and New Zealand Clinical Trial Registry, ACTRN12616000028404.


Subject(s)
Humans , Bipolar Disorder/drug therapy , Garcinia mangostana/chemistry , Depressive Disorder/drug therapy , Fruit/chemistry , Antioxidants/therapeutic use , Placebos/therapeutic use , Quality of Life , Australia
10.
Rev. homeopatia (Säo Paulo) ; 82(3/4): 34-37, 2019.
Article in Portuguese | LILACS, HomeoIndex | ID: biblio-1049891

ABSTRACT

Os autores realizaram um estudo piloto, na Associação Paulista de Homeopatia, para averiguar os efeitos de placebo e medicação homeopática sobe os níveis pressóricos de pacientes portadores de hipertensão arterial sistêmica idiopática. Foram estudados 19 pacientes em uso concomitante ou não de drogas hipotensoras, sendo 14 do sexo feminino, com idade média de 53 anos, e 5 do sexo masculino, com idade média de 44 anos. Fez-se uso do medicamento homeopático único, escolhido por totalidade sintomática característica, nas dinamizações 6C, 12C, 30C, 200C, em doses repetidas, 2 vezes ao dia, por 4 semanas cada. Todos os pacientes receberam previamente placebo por um período de 4 semanas (fase "washout"). Constatou-se efeito significativo da terapêutica homeopática, porém, dentro de uma dinamização individualizada para cada paciente, além da individualização do medicamento. Os autores finalmente fazem considerações para estudos futuros. (AU)


The authors performed a pilot study at the São Paulo Medical Homeopathic Association to investigate the effects of placebo and homeopathic treatment on the blood pressure of patients with idiopathic hypertension. We analyzed 19 patients concomitantly using or not antihypertensive agents, 14 females, with average age 53 years old, and 5 males, with average age 44 years old. One single homeopathic drug was selected as per the total set of characteristic symptoms, and prescribed in dilutions 6C, 12C, 30C and 200C, in repeated doses, twice per day, over 4 weeks each. All the patients previously received placebo over 4 weeks (washout). We found significant effect of homeopathic treatment, however, only for the best individual dilution, in addition to the individualization of the prescribed drugs. The authors finally make some considerations relative to future studies. (au)


Subject(s)
Humans , Male , Female , Middle Aged , Hypertension/therapy , Antihypertensive Agents/therapeutic use , Placebos/therapeutic use , Homeopathic Therapeutics
11.
Einstein (Säo Paulo) ; 17(2): eGS4414, 2019. tab, graf
Article in English | LILACS | ID: biblio-989781

ABSTRACT

ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted Life Years. Abiraterone led to a Quality-Adjusted Life Years gain of 0.506 compared to docetaxel. The incremental costs per Quality-Adjusted Life Years were R$ 133.649,22 for docetaxel, R$ 330.828,70 for abiraterone and R$ 571.379,42 for abiraterone compared to docetaxel, respectively. Conclusion The addition of chemotherapy to androgen deprivation therapy is more cost-effective than the addition of abiraterone to androgen deprivation therapy. However, discounts on abiraterone cost might improve cost-effectiveness.


RESUMO Objetivo Avaliar a relação custo-efetividade da adição de quimioterapia ou abiraterona à terapia de privação hormonal. Métodos Um modelo analítico foi desenvolvido para determinar a relação custo-efetividade da adição de docetaxel ou abiraterona comparada à terapia de privação hormonal isolada. Custos diretos e indiretos foram incluídos no modelo. Os efeitos foram expressos em Anos de Vida Ajustados para Qualidade corrigidos pelos efeitos colaterais de cada terapia. Resultados A adição de quimioterapia e de abiraterona à terapia de privação hormonal aumentou os Anos de Vida Ajustados para Qualidade em 0,492 e 0,999, respectivamente, em comparação à terapia de privação hormonal isolada. A abiraterona promoveu ganho de Anos de Vida Ajustados para Qualidade de 0,506 em relação ao docetaxel. O custo incremental por Anos de Vida Ajustados para Qualidade foi R$ 133.649,22 para o docetaxel, R$ 330.828,70 para a abiraterona e R$ 571.379,42 para a abiraterona comparada ao docetaxel. Conclusão A adição de quimioterapia à terapia de privação hormonal é mais custo-efetiva que a adição de abiraterona à terapia de privação hormonal. Contudo, descontos no custo da abiraterona poderiam tornar esse tratamento mais custo-efetivo.


Subject(s)
Humans , Male , Prostatic Neoplasms/economics , Prostatic Neoplasms/drug therapy , Cost-Benefit Analysis/methods , Antineoplastic Agents, Hormonal/economics , Docetaxel/economics , Androgen Antagonists/economics , Androstenes/economics , Placebos/economics , Placebos/therapeutic use , Prostatic Neoplasms/mortality , Reference Values , Time Factors , Brazil , Antineoplastic Combined Chemotherapy Protocols/economics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Reproducibility of Results , Treatment Outcome , Quality-Adjusted Life Years , Antineoplastic Agents, Hormonal/therapeutic use , Docetaxel/therapeutic use , Progression-Free Survival , Androgen Antagonists/therapeutic use , Androstenes/therapeutic use
12.
Rev. homeopatia (Säo Paulo) ; 82(3/4): 38-41, 2019.
Article in Portuguese | LILACS, HomeoIndex | ID: biblio-1049903

ABSTRACT

Os autores realizaram um estudo piloto de investigação clínica, no ambulatório da Associação Paulista de Homeopatia, para verificar os efeitos de placebo e de medicamentos homeopáticos, escolhidos por totalidade sintomática característica individual, com um grupo de pacientes portadores de hipertensão arterial. Foi enfocada a capacidade de atuação do placebo e de dinamizações sucessivas de medicamento único, 6C, 12C, 30C e 200C, em doses repetidas, 2 vezes ao dia, na referida totalidade sintomatológica, considerando-se seu desaparecimento ou melhoria. Placebo e homeopatia foram fornecidos em frascos idênticos, a cada 4 semanas, começando pelo placebo, até atingir a 200C. Consultas de controle a cada 2 semanas. Concluise pela significância do medicamento homeopático, que não produziu praticamente agravações ou patogenesias, em doses repetidas. A partir da experiência, os autores sugeres condições melhores para feitura de trabalhos semelhantes, para uma melhor avaliação estatística. (AU)


Nineteen patients with idiopathic high blood pressure were subjected to treatment with placebo and homeopathic medicines. Their effects on the characteristic symptoms used to select the individual medication of each patients were analyzed. Statistically significant effect was found for the homeopathic drugs. No aggravation of pathogenetic symptoms practically occurred with doses taken twice daily. Based on their experience, the authors suggest how to improve studies in this field. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Clinical Evolution , Homeopathic Remedy , Hypertension/drug therapy , Placebos/therapeutic use , Dynamization , Treatment Outcome
13.
Int. j. cardiovasc. sci. (Impr.) ; 30(4): f:325-l:333, jul.-ago 2017. tab, graf
Article in Portuguese | LILACS | ID: biblio-846792

ABSTRACT

Fundamentos: Estudos mostram que a administração crônica de chá verde reduz a pressão arterial (PA) de repouso, enquanto que uma única sessão de exercício também promove redução da PA. Objetivo: Investigar se uma única dose de chá verde antes da sessão de exercício melhora a hipotensão pós exercício (HPE). Métodos: Estudo randomizado, placebo-controlado, duplo cego. Quinze pacientes hipertensos (53 ± 3,3 anos) participaram de duas sessões: chá verde + exercício (CVE) e placebo + exercício (PLE). Trinta minutos após ingestão de 2 g de chá verde ou placebo, os pacientes realizaram 60 minutos de caminhada na esteira a 60-85% da frequência cardíaca máxima. A PA foi medida em repouso e a cada 10 minutos após o exercício por 60 minutos. As amostras de sangue foram colhidas antes da ingestão do chá verde ou placebo e imediatamente após o exercício para determinar as concentrações de malondialdeído (MDA) e nitrito (NO). Resultados: No dia PLE, a HPE foi detectada em todos os tempos pós-exercício (redução na PA de 6,5 a 11,8 mmHg), enquanto que no dia CVE, HPE ocorreu somente aos 20 e 40 minutos pós-exercício, respectivamente. A redução na pressão sanguínea foi significativamente maior no PLE aos 10, 20 e 30 minutos pós-exercício em comparação a CVE. Além disso, CVE causou uma resposta diastólica hipertensiva, enquanto no dia PLE, a HPE diastólica foi observada somente aos 20 minutos pós-exercício. Não foram observadas mudanças nas concentrações de MDA ou NO em resposta ao exercício. Conclusão: A suplementação com chá verde anterior a uma sessão de exercício aeróbico atenuou a HPE sistólica e induziu uma resposta hipertensiva ao exercício aeróbico em pacientes hipertensos


Background: Studies have shown that chronic administration of green tea decreases blood pressure (BP) at rest, while a single exercise session also promotes reduction of BP. Objective: To investigate whether if a single dose of green tea prior to aerobic exercise session improves post-exercise hypotension (PEH). Methods: Randomized, double-blind, placebo controlled study. Fifteen hypertensive patients (53 ± 3.3 years) participated in two study sessions: green tea+exercise (GTE) and placebo+exercise (PLE). Thirty minutes after ingesting 2g of green tea or placebo, they performed 60 minutes of treadmill walking at 60 to 85% of maximum heart rate. BP was measured at rest and at every 10 minutes after exercise for 60 minutes. Blood samples were taken before ingestion of green tea or placebo and immediately after exercise to determine malondialdehyde (MDA) and nitrite (NO) concentrations. Results: On PLE day, systolic PEH was detected at all post-exercise time points (BP reduction by 6.5-11.8 mmHg), whereas on GTE day, PEH was found only at 20 and 40 minutes post-exercise (BP reduction by 5.9 and 5.8 mmHg, respectively). BP reduction was significantly higher in PLE at 10, 20 and 30 minutes post-exercise compared with GTE. In addition, GTE resulted in hypertensive diastolic response, while on PLE day, diastolic PEH was seen only at 20 minutes post-exercise. No changes in MDA or NO concentrations in response to exercise were observed. Conclusion: Green tea supplementation prior to an aerobic exercise session attenuated systolic PEH and induced diastolic hypertensive response to aerobic exercise in hypertensive patients


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Camellia sinensis/drug effects , Exercise , Hypotension/therapy , Placebos/therapeutic use , Analysis of Variance , Antioxidants/therapeutic use , Arterial Pressure , Blood Specimen Collection/methods , Double-Blind Method , Hypertension/therapy , Oxidative Stress , Treatment Outcome
14.
Braz. j. med. biol. res ; 49(6): e4806, 2016. tab, graf
Article in English | LILACS | ID: biblio-951682

ABSTRACT

New generation antidepressant therapies, including serotonin-norepinephrine reuptake inhibitor (SNRIs), were introduced in the late 1980s; however, few comprehensive studies have compared the benefits and risks of various contemporary treatments for major depressive disorder (MDD) in young patients. A comprehensive literature search of PubMed, Cochrane, Embase, Web of Science, and PsycINFO databases was conducted from 1970 to January 2015. Only clinical trials that randomly assigned one SNRI or placebo to patients aged 7 to 18 years who met the diagnostic criteria for major depressive disorder were included. Treatment success, dropout rate, and suicidal ideation/attempt outcomes were measured. Primary efficacy was determined by pooling the risk ratios (RRs) of treatment response and remission. Acceptability was determined by pooling the RRs of dropouts for all reasons and for adverse effects as well as suicide-risk outcomes. Five trials with a total of 973 patients were included. SNRIs were not significantly more effective than placebo for treatment response but were for remission. The comparison of patients taking SNRIs that dropped out for all reasons and those taking placebo did not reach statistical significance. Significantly more patients taking SNRIs dropped out for adverse effects than those taking placebo. No significant difference was found in suicide-related risk outcomes. SNRI therapy does not display a superior efficacy and is not better tolerated compared to placebo in these young patients. However, duloxetine has a potential beneficial effect for depression in young populations, showing a need for further research.


Subject(s)
Humans , Male , Female , Child , Adolescent , Randomized Controlled Trials as Topic , Depressive Disorder, Major/drug therapy , Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use , Antidepressive Agents/therapeutic use , Placebos/therapeutic use , Cyclopropanes/therapeutic use , Desvenlafaxine Succinate/therapeutic use , Duloxetine Hydrochloride/therapeutic use , Milnacipran
16.
Rev. cuba. hematol. inmunol. hemoter ; 30(3): 214-222, jul.-set. 2014.
Article in Spanish | LILACS | ID: lil-723759

ABSTRACT

Se denomina placebo a una intervención diseñada para simular una terapia médica, que no tiene efectos específicos para la condición que está siendo aplicada. El efecto placebo es la modificación, muchas veces fisiológicamente demostrable, que se produce en el organismo como resultado del estímulo psicológico inducido por la administración de una sustancia inerte, de un fármaco o de un tratamiento. En este trabajo se abordan las definiciones de placebo, el origen de este término, los factores y mecanismos que intervienen en el efecto placebo, así como el uso de los placebos en la práctica médica y en la investigación clínica...


Placebo is an intervention designed to simulate a medical therapy, which has no specific effects for the condition that is being applied. The placebo effect is the change, often physiologically provable, which is produced in the body as a result of a psychological stimulus induced by the administration of an inert substance, a drug or a treatment. We hereby include the definition of placebo, the origin of this word, the factors and mechanisms involved in the placebo effect, and the use of placebos in medical practice and clinical research...


Subject(s)
Humans , Placebo Effect , Placebos/history , Placebos/therapeutic use , Review Literature as Topic
17.
Rev. bioét. (Impr.) ; 22(1): 28-33, jan.-abr. 2014.
Article in Spanish | LILACS | ID: lil-710045

ABSTRACT

La Declaración de Helsinki 1964 ha sido sometida a numerosas revisiones y enmiendas, la más reciente siendo Fortaleza (2013), una frecuencia considerada necesaria dado los avances de la medicina contemporánea, pero también criticada por restarle estabilidad y autoridad al documento. La versión de Edimburgo (2000) enfatizó la tolerancia al uso de placebos y restó apoyo de los beneficios post-estudio para los probandos y la comunidad huésped, pese a los esfuerzos de Argentina y Brasil por robustecer la protección de las personas incorporadas a los estudios. Queda aceptado - de hecho - el doble estándar en la ética de investigación que debilita la Declaración como normativa ética de la investigación con seres humanos. La dominancia acentuada de los intereses corporativos de investigadores y patrocinadores sugiere que la bioética latinoamericana debiera desarrollar su propio documento normativo, en respeto a nuestra realidad social, y enfocado a la protección de las comunidades de la región...


A Declaração de Helsinki de 1964 vem sendo submetida a numerosas revisões e emendas, sendo a mais recente a de Fortaleza (2013). A frequência dessas reformulações tem sido considerada necessária, dados os avanços da medicina contemporânea, mas também criticada por conferir pouca estabilidade e autoridade ao documento. A versão de Edimburgo (2000) marcou a política de tolerância ao uso de placebo e de escasso apoio aos benefícios pós-estudo aos sujeitos e à comunidade, desestimulando os esforços da Argentina e Brasil para reforçar a proteção aos participantes dos estudos. Se aceita assim - de fato - o duplo standart em ética em pesquisa, que de forma progressiva debilita a Declaração como normativa ética para a pesquisa envolvendo seres humanos. A dominação cada vez mais acentuada de interesses corporativos de investigadores e patrocinadores sugere que a bioética latino-americana deve desenvolver seu próprio documento normativo, em respeito a nossa realidade social, voltado a proteção às comunidades da região...


The original Declaration of Helsinki (1964) has been subjected to numerous revisions and reformulations, supposedly necessary to keep apace with medical progress, but in fact leading to its loss of stability and authority. The Edinburgh 2000 revision made provisions for increased tolerance in the use of placebos, and loss of commitment to assure post-investigational benefits to individuals and communities involved. In spite of Argentina's and Brazil's manifest opposition, a double standard for research ethics became a de facto reality which has increasingly weakened the Declaration. Corporative interests of major stakeholders -researchers and sponsors- have been strongly supported as the Declaration becomes less protective of individuals and communities involved. It is therefore suggested that Latin American bioethicists would be well advised to develop a regionally pertinent normative in accordance with our social reality and the need of protecting our population...


Subject(s)
Humans , Male , Female , Bioethics , Clinical Protocols , Clinical Trials as Topic , Ethics, Research , Protective Factors , Drug Industry , Placebos/therapeutic use
18.
Belo Horizonte; s.n; 2014. 61 p. ilus, tab, graf.
Thesis in Portuguese | LILACS, BBO | ID: lil-790341

ABSTRACT

O alendronato de sódio é utilizado, na área médica, no tratamento da osteoporose e outras doenças ósseas. Nos últimos anos alguns estudos avaliaram o efeito do uso sistêmico do alendronato, principalmente, em defeitos ósseos decorrentes da evolução da doença periodontal inflamatória. Todavia, o uso sistêmico e prolongado do alendronato tem sido associado à osteonecrose dos maxilares. O objetivo deste ensaio clínico controlado randomizado foi avaliar o efeito do tratamento periodontal mecânico não cirúrgico, associado à aplicação tópica de alendronato de sódio a 1%, em indivíduos com periodontite. Para tanto, 16 indivíduos com periodontite crônica foram selecionados nas clínicas de Periodontia do Departamento de Odontologia da Pontifícia Universidade Católica de Minas Gerais, no período de abril de 2013 a maio de 2014...


Alendronate Sodium is medically used in the treatment of osteoporosis and other bone diseases. In the past few years, studies have evaluated the effect of systemic use of Alendronate Sodium, especially in the treatment of structural bone defects caused by the evolution of periodontal inflammatory diseases. However, the prolonged and systemic use of Alendronate Sodium has been associated with the treatment of osteonecrosis of the maxilla. The objective of this randomized and controlled clinical trial was to evaluate the effect of non-surgical mechanical periodontal treatment, associated with the topical application of Alendronate Sodium at 1%, to individuals presenting cases of periodontitis. To the case, 16 individuals presenting chronic periodontitis were selected in the periodontal clinics of the Odontology department from the Pontifícia Universidade Católica de Minas Gerais, in the period of April of 2013 to May of 2014. A complete periodontal exam was performed three and six months after the base exam, registeringthe following clinical parameters: probing depth, measured insertion loss, bleeding on probing, plaque index. The evaluation of the bone defects was performed using the technics of subtraction radiography and cone beam computerized tomography in the base exam and six months after the non-surgical ...(AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Alendronate/therapeutic use , Periodontal Diseases/therapy , Chronic Periodontitis/therapy , Placebos/therapeutic use , Bone Resorption , Diphosphonates , Subtraction Technique , Cone-Beam Computed Tomography
19.
Journal of Korean Medical Science ; : 12-22, 2014.
Article in English | WPRIM | ID: wpr-53762

ABSTRACT

Although pharmacological treatment constitutes the main therapeutic approach for depression, non-pharmacological treatments (self-care or psychotherapeutic approach) are usually regarded as more essential therapeutic approaches in clinical practice. However, there have been few clinical practice guidelines concerning self-care or psychotherapy in the management of depression. This study introduces the 'Evidence-Based, Non-Pharmacological Treatment Guideline for Depression in Korea.' For the first time, a guideline was developed for non-pharmacological treatments for Korean adults with mild-to-moderate depression. The guideline development process consisted of establishing several key questions related to non-pharmacologic treatments of depression, searching the literature for studies which answer these questions, assessing the evidence level of each selected study, drawing up draft recommendation, and peer review. The Scottish Intercollegiate Guidelines Network grading system was used to evaluate the quality of evidence. As a result of this process, the guideline recommends exercise therapy, bibliotherapy, cognitive behavior therapy, short-term psychodynamic supportive psychotherapy, and interpersonal psychotherapy as the non-pharmacological treatments for adult patients with mild-to-moderate depression in Korea. Hence, it is necessary to develop specific methodologies for several non-pharmacological treatment for Korean adults with depression.


Subject(s)
Adult , Humans , Bibliotherapy/methods , Clinical Protocols , Cognitive Behavioral Therapy/methods , Combined Modality Therapy/methods , Depression/drug therapy , Exercise Therapy , Placebos/therapeutic use , Surveys and Questionnaires , Republic of Korea
20.
Rev. cuba. invest. bioméd ; 32(3): 366-378, jul.-sep. 2013.
Article in Spanish | LILACS | ID: lil-705689

ABSTRACT

Introducción: quizás ningún otro término haya sido tan indebidamente utilizado y causado tanta confusión como ®placebo». Sus efectos han potenciado los tratamientos médicos en la historia sin el debido reconocimiento. Entendido como eventos atribuibles al significado que adquiere una intervención dentro de un contexto terapéutico dado, se redimensiona y aleja de las definiciones tautológicas dominantes. Objetivo: analizar los retos que esta postura teórica plantea, así como sus potencialidades para la investigación y la práctica clínica. Métodos: Se analizan las limitaciones de su uso en Ensayos Clínicos Aleatorizados, entre las que se destaca la paradoja de la eficacia. Se contrasta la evidencia sobre su efectividad, generada en distintos contextos. Se describen los placebos disponibles en la práctica clínica y situaciones de uso; así como las opiniones de médicos y pacientes. Se introduce su efecto desde la dimensión biopsicosocial, dentro de la Medicina del Estilo de Vida. Se esbozan razones que impiden a las medicinas alternativas ®ser mejor que un placebo». Por último, se identifica y ejemplifica su espacio dentro la práctica clínica. Conclusiones: el efecto del placebo debe ser comprendido como un efecto del contexto, estructurado sobre la base del significado individual asignado a la intervención dentro de una cultura e historia específicas, que resulta significativo sobre numerosas enfermedades, mediante la activación y modificación variables psicológicas y fisiológicas. Concebido como Ambiente Curativo Óptimo, adquiere el ®principio activo» necesario para actuar por sí mismo (cuando la alternativa es no hacer nada), o potenciando el efecto de los tratamientos convencionales


Introduction: no term has probably been as misused and has caused so much confusion as the term `placebo'. Its effects have strengthened medical treatments throughout history without receiving due recognition. Understood as events attributable to the significance acquired by an intervention in a given therapeutic context, it takes on a new dimension, detaching from the prevailing tautological definitions. Objective: analyze the challenges posed by this theoretical stand, as well as its potential for research and clinical practice. Method: an analysis is conducted of the limitations of its use in randomized clinical trials, among them the efficacyparadox. A contrast is made of evidence of its effectiveness generated in various contexts. A description is provided of placebos available in clinical practice and situations of use, as well as doctors' and patients' opinions. Its effect is presented from a biopsychosocial perspective, within the framework of Lifestyle Medicine. An outline is provided of the factors preventing alternative medicines from being ®better than a placebo». Finally, its place in clinical practice is identified and exemplified. Conclusions: the placebo effect should be understood as an effect from the context, structured on the basis of the individual significance assigned to the intervention by a specific culture and historical development, which is significant for a large number of diseases, through the activation and modification of psychological and physiological variables. Conceived of as an Optimal Healing Environment, it acquires the ®active principle» required to act by itself (when the alternative is doing nothing), or strengthen the effect of conventional treatments


Subject(s)
Placebos/administration & dosage , Placebos/history , Placebos/therapeutic use , Placebo Effect
SELECTION OF CITATIONS
SEARCH DETAIL